Piramal Pharma's Q3 FY 2025-26 Quarterly Results
- 29 Jan 2026
Result Summary
- Piramal Pharma Ltd reported a 3.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 1.5%.
- Its expenses for the quarter were up by 3.5% QoQ and 3.7% YoY.
- The net profit increased 37.3% QoQ and decreased 3800.8% YoY.
- The earnings per share (EPS) of Piramal Pharma Ltd declined at 1.03 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 2183.11 | 2109.32 | 2216.35 | 3.5% | -1.5% |
Total Expenses | 2246.12 | 2170.29 | 2166.60 | 3.5% | 3.7% |
Profit Before Tax | -104.12 | -60.97 | 49.75 | 70.8% | -309.3% |
Tax | 42.33 | 53.04 | 63.12 | -20.2% | -32.9% |
Profit After Tax | -136.19 | -99.22 | 3.68 | 37.3% | -3800.8% |
Earnings Per Share | -1.03 | -0.75 | 0.03 | 37.3% | -3533.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Piramal Pharma Ltd is a prominent player in the pharmaceutical industry, known for its wide range of products and services. The company operates in the healthcare sector, focusing on pharmaceutical solutions, critical care, and consumer products. While specific recent developments of the company are not provided, Piramal Pharma has historically been involved in various strategic initiatives to expand its market reach and enhance its product offerings. The company is part of the broader pharmaceutical industry, which is subject to regulatory changes, innovation-driven growth, and competitive pressures.
Revenue
For the third quarter of the fiscal year 2026 (Q3FY26), Piramal Pharma Ltd reported total income of ₹2183.11 crores. This represents a quarter-over-quarter (QoQ) increase of 3.5% from ₹2109.32 crores in Q2FY26. However, when compared year-over-year (YoY) to Q3FY25, there is a slight decrease of 1.5% from ₹2216.35 crores. The revenue performance, as indicated by these figures, reflects the company's ability to maintain a stable income stream despite slight fluctuations over the year.
Profitability
In Q3FY26, Piramal Pharma Ltd recorded a Profit Before Tax (PBT) of -₹104.12 crores, a significant increase in loss from -₹60.97 crores in Q2FY26, marking a 70.8% QoQ change. Compared to Q3FY25, where the company had a PBT of ₹49.75 crores, the YoY change is -309.3%. The Profit After Tax (PAT) for Q3FY26 stands at -₹136.19 crores, increasing the loss from -₹99.22 crores in the previous quarter, and significantly down from ₹3.68 crores in Q3FY25, with a YoY decrease of -3800.8%. The Earnings Per Share (EPS) also reflect this trend, with Q3FY26 EPS at -₹1.03 compared to -₹0.75 in Q2FY26 and ₹0.03 in Q3FY25, showing a YoY change of -3533.3%.
Operating Metrics
The total expenses for Piramal Pharma Ltd in Q3FY26 were ₹2246.12 crores, up 3.5% QoQ from ₹2170.29 crores in Q2FY26, and a 3.7% increase YoY from ₹2166.60 crores in Q3FY25. The tax expenses decreased by 20.2% QoQ from ₹53.04 crores in Q2FY26 to ₹42.33 crores in Q3FY26, and by 32.9% YoY from ₹63.12 crores in Q3FY25. These figures indicate that while the company has increased its spending, it has simultaneously managed to reduce its tax liabilities. The overall financial performance for this quarter highlights certain areas of financial strain, as reflected in the reported losses and expenses.